Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERONASDAQ:CGIXNASDAQ:GRAYNASDAQ:PBM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$0.53+1.0%$0.74$0.49▼$109.00$4.09M0.66803,937 shs246,733 shsCGIXCancer Genetics$0.19$0.26$2.11▼$17.50$792K2.722.44 million shs19,116 shsGRAYGraybug Vision$1.80+5.3%$1.80$5.00▼$22.12$2.83M1.22,165 shs3,846 shsPBMPsyence Biomedical$4.39-0.7%$4.24$2.92▼$699.19$2.50M-0.11103,546 shs26,596 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics0.00%-9.40%-52.25%-70.14%-99.46%CGIXCancer Genetics0.00%0.00%0.00%0.00%0.00%GRAYGraybug Vision+5.26%-10.00%+17.65%-23.40%-66.67%PBMPsyence Biomedical0.00%-15.58%+19.22%-57.63%-99.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCEROCERo Therapeutics3.0245 of 5 stars3.72.00.00.03.00.80.0CGIXCancer GeneticsN/AN/AN/AN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 3.33Buy$7.001,220.75% UpsideCGIXCancer Genetics 0.00N/AN/AN/AGRAYGraybug Vision 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CGIX, GRAY, CERO, and PBM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025CEROCERo TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/22/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/22/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$11.00 ➝ $11.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($259.05) per shareN/ACGIXCancer Genetics$6.33M0.13N/AN/AN/A∞GRAYGraybug VisionN/AN/AN/AN/A$1.67 per shareN/APBMPsyence BiomedicalN/AN/AN/AN/A($61.61) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$2.54MN/A0.00∞N/AN/AN/A-108.43%N/ACGIXCancer GeneticsN/A-$2.07N/A∞N/AN/AN/AN/AN/AGRAYGraybug Vision-$35.60M-$24.23N/AN/AN/AN/A-77.61%-71.34%N/APBMPsyence Biomedical-$51.16MN/A0.00∞N/AN/AN/AN/AN/ALatest CGIX, GRAY, CERO, and PBM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025N/ACEROCERo TherapeuticsN/A-$1.59N/A-$1.59N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/ACGIXCancer GeneticsN/AN/AN/AN/AN/AGRAYGraybug VisionN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.390.39CGIXCancer GeneticsN/AN/AN/AGRAYGraybug VisionN/A10.7310.72PBMPsyence BiomedicalN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%CGIXCancer Genetics8.92%GRAYGraybug Vision49.94%PBMPsyence Biomedical77.44%Insider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics12.72%CGIXCancer Genetics15.00%GRAYGraybug Vision7.94%PBMPsyence Biomedical3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics87.72 million2.49 millionN/ACGIXCancer GeneticsN/A4.09 millionN/ANot OptionableGRAYGraybug Vision271.57 million20.25 millionNot OptionablePBMPsyence BiomedicalN/A570,0006.36 millionN/ACGIX, GRAY, CERO, and PBM HeadlinesRecent News About These CompaniesPsyence Biomedical Ltd. WtMay 21, 2025 | marketwatch.comPsyence Biomedical Advances Psilocybin Drug Development as of May 2025May 20, 2025 | tipranks.comPsyence Biomedical announces reverse stock splitMay 2, 2025 | investing.comPsyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock SplitMay 1, 2025 | newsfilecorp.comPsyence Group consolidates its sharesApril 18, 2025 | greenmarketreport.comPsyence BioMed gets Nasdaq notice for non-complianceApril 18, 2025 | msn.comPsyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 17, 2025 | newsfilecorp.comPsyence Group Inc.: Psyence Group Announces Share ConsolidationApril 17, 2025 | finanznachrichten.dePsyence Group Announces Share ConsolidationApril 17, 2025 | globenewswire.comPsyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply dealApril 16, 2025 | greenmarketreport.comPsyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply AgreementApril 15, 2025 | newsfilecorp.comPsyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in AustraliaApril 8, 2025 | newsfilecorp.comPsyence Biomedical reports corporate updateApril 3, 2025 | investing.comPsyence BioMed Advances in Psychedelic Medicine with Strategic Growth and Clinical TrialsApril 1, 2025 | tipranks.comCorporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable ManufacturingMarch 31, 2025 | newsfilecorp.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Further Strengthens Scientific Advisory Board With Appointment of Dr. Dan J. SteinMarch 25, 2025 | markets.businessinsider.comPsyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. SteinMarch 18, 2025 | newsfilecorp.comPsyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.March 10, 2025 | globenewswire.comPsyence Biomedical files $75M mixed securities shelfMarch 4, 2025 | markets.businessinsider.comPsyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory BoardFebruary 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCGIX, GRAY, CERO, and PBM Company DescriptionsCERo Therapeutics NASDAQ:CERO$0.53 +0.01 (+0.95%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.53 0.00 (-0.57%) As of 05/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Cancer Genetics NASDAQ:CGIXVyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson's Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.Graybug Vision NASDAQ:GRAY$1.80 +0.09 (+5.26%) As of 05/23/2025Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.Psyence Biomedical NASDAQ:PBM$4.39 -0.03 (-0.68%) Closing price 05/23/2025 03:55 PM EasternExtended Trading$4.30 -0.09 (-1.94%) As of 05/23/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
